Screener
Dyne Therapeutics, Inc. DYN EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other expense, net | (133) | (89) |
| Total other income, net | 4,422 | 7,011 |
| Net loss | $(120,854) | $(115,361) |
| Net loss per share—basic and diluted | $(0.73) | $(1.05) |
| Weighted average common shares outstanding, basic and diluted | 165,036,604 | 109,911,628 |
| Comprehensive loss: | ||
| Net loss | $(120,854) | $(115,361) |
| Other comprehensive loss: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s EPS (basic)?
- Dyne Therapeutics, Inc. (DYN) reported EPS (basic) of -$0.73 in Q1 2026.
- How has Dyne Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Dyne Therapeutics, Inc.'s EPS (basic) increased by 30.5% year-over-year, from -$1.05 to -$0.73.
- What is the long-term trend for Dyne Therapeutics, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s EPS (basic) has grown at a 4.6% compound annual growth rate (CAGR), from -$2.93 to -$3.51.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Dyne Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude